spacer
home > ebr > summer 2004 > the ipo window reopens - are you ready?
PUBLICATIONS
European Biopharmaceutical Review

The IPO Window Reopens - Are you Ready?

Whisper it quietly, but the IPO window may just have reopened for European biotechs. Ark Therapeutics' flotation in March this year has led to a spate of similar launches of biotech stocks onto the public markets after a dearth of opportunities in recent years. The position undoubtedly remains volatile. Only the best companies will be allowed to list and, as ever, due diligence will be key. This article looks at the importance of legal due diligence in the context of an impending IPO and asks are you ready to take advantage of the IPO window - which may yet prove shortlived.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Patrick Martin, Partner and Martin Finnegan, Senior Solicitor at McGrigors

Patrick Martin is a Partner and Corporate and Commercial Lawyer at McGrigors, with a particular emphasis on the health care and life sciences fields, acting for both investors and companies. He has advised on numerous technology start-ups and spin-outs, fundraisings and private placements for biotech companies and IPOs. Patrick has specialised in private equity work for over 14 years.


Martin Finnegan is a senior Corporate Solicitor at McGrigors and part of the firm's public equity group. Martin has advised on numerous IPOs and public equity issues acting for sponsors and companies, and is a member of the legal committee of the Quoted Companies Alliance (QCA).

spacer
Patrick Martin
spacer
spacer
spacer
Martin Finnegan
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Nemera announces a better drug deposition with RetroNose to enhance therapeutic efficacy of nasal treatments

After announcing a partnership with the Research Center for Respiratory Diseases (CEPR) of Inserm/University of Tours in April 2017, Nemera is happy to publish enhanced drug deposition results compared to classic nasal sprays with RetroNose.
More info >>

White Papers

Accelerate Your Database Lock Using Clean Patient Optics

Bioclinica

Because a key step towards database lock is obtaining clean data for all patients, the ability to verify that data are clean early accelerates the ability to lock the clinical database. This ultimately shortens the overall study timeline while ensuring the quality of your data. However, this can be challenging when manually reviewing study data, particularly with larger studies.
More info >>

 
Industry Events

World Pharma Week 2019

17-20 June 2019, Seaport World Trade Center, Boston

World Pharma Week will bring together a unique and international mix of large and medium pharmaceutical and biotech companies, CROs, leading universities and clinical research institutions, emerging companies and tool providers—making it a perfect meeting-place to share experience, foster collaborations across industry and academia, and evaluate emerging technologies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement